{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:21:32Z","timestamp":1790936492386,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.jhep.2005.11.025","type":"journal-article","created":{"date-parts":[[2005,12,2]],"date-time":"2005-12-02T12:24:58Z","timestamp":1133526298000},"page":"S119-S125","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S1","title":["Antiviral hepatitis and antiretroviral drug interactions"],"prefix":"10.1016","volume":"44","author":[{"given":"Christian","family":"Perronne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2005.11.025_bib1","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/00002030-200311070-00002","article-title":"Update on chronic hepatitis C in HIV\u2013HCV co-infected patients: viral interactions and therapy","volume":"17","author":"Bra\u00fc","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib2","first-page":"528","article-title":"Aspects th\u00e9rapeutiques de la co-infection par les virus de l'immunod\u00e9ficience humaine et des h\u00e9patites B et C","volume":"27","author":"Bani-Sadr","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2005.11.025_bib3","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2174\/1381612043384286","article-title":"Therapy of chronic hepatitis C virus infection in HIV co-infected people","volume":"10","author":"Fabris","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhep.2005.11.025_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1310\/GEUC-NGKM-XUGU-4X94","article-title":"New hopes for HIV and HCV co-infection in 2004","volume":"5","author":"Nunez","year":"2004","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jhep.2005.11.025_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200401020-00001","article-title":"Care of patients with hepatitis C and HIV co-infection","volume":"18","author":"Soriano","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(04)01059-X","article-title":"HIV and hepatitis C virus co-infection","volume":"4","author":"Rockstroh","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib7","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1001\/jama.292.23.2909","article-title":"Treatment of hepatitis C in HIV-infected patients. Significant progress but not the final step","volume":"292","author":"Manns","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jhep.2005.11.025_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1046\/j.1468-1293.2001.00066.x","article-title":"Peripheral neuropathy during stavudine\u2013didanosine antiretroviral therapy","volume":"2","author":"Reliquet","year":"2001","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002030-200002180-00009","article-title":"Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea","volume":"14","author":"Moore","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib10","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib11","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature","volume":"34","author":"Falco","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(99)00169-2","article-title":"Acute pancreatitis in human immunodeficiency virus-infected patients: a review","volume":"107","author":"Dassopoulos","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(00)04579-7","article-title":"Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia","volume":"357","author":"Carr","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1258\/0956462001916498","article-title":"Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases","volume":"11","author":"Ter Hofstede","year":"2000","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/313912","article-title":"Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens","volume":"31","author":"Lonergan","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/313594","article-title":"Lactic acidosis associated with stavudine administration: a report of five cases","volume":"30","author":"Mokrzycki","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/00002030-200211080-00009","article-title":"Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors","volume":"16","author":"Walker","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib20","first-page":"150","article-title":"Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies","volume":"3","author":"Moyle","year":"2001","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jhep.2005.11.025_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/00002030-200207050-00005","article-title":"Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors","volume":"16","author":"Moyle","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib22","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1086\/323980","article-title":"Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series","volume":"33","author":"Delgado","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib23","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1111\/j.1572-0241.1999.01294.x","article-title":"Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings","volume":"94","author":"Barbaro","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.11.025_bib24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/gast.2002.30983","article-title":"Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein","volume":"122","author":"Okuda","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.11.025_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/gast.2000.8528","article-title":"Acute pancreatitis attributed to the use of interferon alfa-2b","volume":"119","author":"Eland","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.11.025_bib26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.2435003","article-title":"Ribavirin antagonizes the effect of azidothymidine on HIV replication","volume":"235","author":"Vogt","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jhep.2005.11.025_bib27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/AAC.31.10.1613","article-title":"Ribavirin antagonizes inhibitory effects of pyrimidine 2\u2032,3\u2032-dideoxynucleosides but enhances inhibitory effects of purine 2\u2032,3\u2032-dideoxynucleosides on repplication of human immunodeficiency virus in vitro","volume":"31","author":"Baba","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.025_bib28","first-page":"766","article-title":"Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase","volume":"38","author":"Fernandez-Larsson","year":"1990","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2005.11.025_bib29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.39.6.1376","article-title":"Drug interactions with zidovudine phosphorylation in vitro","volume":"39","author":"Hoggard","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.025_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.41.6.1231","article-title":"Effects of drugs on 2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine phosphorylation in vitro","volume":"41","author":"Hoggard","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.025_bib31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1089\/aid.1998.14.1661","article-title":"Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction","volume":"14","author":"Sim","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jhep.2005.11.025_bib32","doi-asserted-by":"crossref","first-page":"21509","DOI":"10.1016\/S0021-9258(18)54668-8","article-title":"Mechanisms of the potentiating effect of ribavirin on the activity of 2\u2032,3\u2032-dideoxyinosine against human immunodeficiency virus","volume":"266","author":"Balzarini","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2005.11.025_bib33","first-page":"118","article-title":"Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2\u2032,3\u2032-dideoxyadenosine and 2\u2032,3\u2032-dideoxyinosine","volume":"40","author":"Hartman","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2005.11.025_bib34","first-page":"1009","article-title":"Ribavirin potentiates the efficacy and toxicity of 2\u2032,3\u2032-dideoxyinosine in the murine acquired immunodeficiency syndrome model","volume":"279","author":"Harvie","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2005.11.025_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00042560-199611010-00005","article-title":"A phase-1 study of the safety, pharmacokinetics, and antiviral activity of combination of didanosine and ribavirin in patients with HIV-1 disease","volume":"13","author":"Japour","year":"1996","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2005.11.025_bib36","first-page":"140","article-title":"Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options","volume":"1","author":"Brinkman","year":"1999","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jhep.2005.11.025_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/infdis\/164.4.646","article-title":"Two drug combinations of zidovudine, didanosine and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type one synergistically in vitro","volume":"164","author":"Johnson","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00002030-200305020-00008","article-title":"Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus","volume":"17","author":"Klein","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/gut.47.5.694","article-title":"Safety and efficacy of interferon ribavirin combination therapy in HCV\u2013HIV co-infected subjects: an early report","volume":"47","author":"Zylberberg","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2005.11.025_bib40","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00002030-200111090-00010","article-title":"Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients","volume":"15","author":"Landau","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/jhep.2001.29130","article-title":"Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders","volume":"34","author":"Sauleda","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.025_bib42","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/00002030-200109280-00006","article-title":"Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin","volume":"15","author":"Nasti","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib43","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jhep.2005.11.025_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/374837","article-title":"Interferon\u2013ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients co-infected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial","volume":"36","author":"Salmon-C\u00e9ron","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/rcm.384","article-title":"Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography tandem mass spectrometry","volume":"15","author":"Pruvost","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.jhep.2005.11.025_bib46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/rcm.605","article-title":"Improved method for the simultaneous determination of d4T, 3TC and ddI intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry","volume":"16","author":"Becher","year":"2002","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.jhep.2005.11.025_bib47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside analogue RT inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib49","first-page":"348","article-title":"Sidebar: editorial comment: drug\u2013drug interactions, hepatitis C, and mitochondrial toxicity","volume":"13","author":"Glesby","year":"2003","journal-title":"AIDS Read"},{"key":"10.1016\/j.jhep.2005.11.025_bib50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(00)04921-7","article-title":"Mitochondrial toxic effects of ribavirin","volume":"357","author":"Salmon-C\u00e9ron","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\u2013HCV co-infection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0168-8278(02)00133-2","article-title":"Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C","volume":"37","author":"Guyader","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2005.11.025_bib53","first-page":"344","article-title":"Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy","volume":"13","author":"Butt","year":"2003","journal-title":"AIDS Read"},{"key":"10.1016\/j.jhep.2005.11.025_bib54","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(00)04920-5","article-title":"Mitochondrial toxic effects of ribavirin","volume":"357","author":"Kakuda","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib55","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","article-title":"Weight loss in HIV-infected patients","volume":"347","author":"Garcia-Benayas","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib56","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/00002030-200012010-00012","article-title":"Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy","volume":"14","author":"G\u00e9rard","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib57","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.025_bib58","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated interferon-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\u2013HCV co-infected patients receiving didanosine","volume":"9","author":"Moreno","year":"2004","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2005.11.025_bib60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-infected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib61","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\u2013HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib62","unstructured":"Smith DM, Puoti M, Sulkowski M, Carosi GP, Gilbert TL, De Pamphilis J, et al. Symptomatic hyperlactatemia during a large HCV treatment trial in HIV\u2013HCV co-infected participants on stable HAART. 14th world AIDS conference, Barcelona, Spain; July 2002. [Abstract MoOrB1059]."},{"key":"10.1016\/j.jhep.2005.11.025_bib63","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/108729101753354608","article-title":"Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis","volume":"15","author":"Dalton","year":"2001","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.jhep.2005.11.025_bib64","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\u2013HCV co-infection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anaemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.025_bib66","unstructured":"Bra\u00fc N, Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Lazzarin A, et al. Safety of peginterferon, alfa-2a (Pegasys) 180 mcg weekly plus ribavirin 800 mg daily in HIV\u2013HCV co-infection compared to HCV mono-infection. 15th world AIDS conference, Bangkok, Thailand; July 2004. [Abstract MoPeB3311]."},{"key":"10.1016\/j.jhep.2005.11.025_bib67","first-page":"2491","article-title":"Once-weekly epoietin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa","volume":"98","author":"Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.11.025_bib68","unstructured":"Dieterich D, Sulkowski M, Bini E, Bra\u00fc N, Newman C, Alvarez D, et al., Epoietin-alpha administered once-weekly improves anemia in HIV\u2013HCV co-infected patients treated with interferon-ribavirin therapy: a prospective randomized study. 11th conference on retroviruses and opportunistic infections, San Francisco, USA; February 2004. [Abstract 824]."},{"key":"10.1016\/j.jhep.2005.11.025_bib69","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/j.gastro.2004.01.027","article-title":"Epoietin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study","volume":"126","author":"Afdhal","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.11.025_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/qjmed\/94.3.153","article-title":"Managing chronic hepatitis C acquired through intravenous drug use","volume":"94","author":"Jowett","year":"2001","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhep.2005.11.025_bib72","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.025_bib73","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2005.11.025_bib74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.11.025_bib75","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1086\/379774","article-title":"Tratment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future","volume":"37","author":"Mayer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s10096-004-1127-3","article-title":"Management of hepatitis B in patients co-infected with the human immunodeficiency virus","volume":"23","author":"Lessells","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib77","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/315711","article-title":"Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients","volume":"182","author":"Molina","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib78","unstructured":"Brundage RC, Acosta E, Haubrich R, Katzenstein D, Gulick R, Fletcher CV. Quantification of sex differences and drug interactions: pharmacologic studies of saquinavir in ACTG 359. Ninth conference on retroviruses and opportunistic infections, Seattle, USA; February 2002. [Abstract 799-W]."},{"key":"10.1016\/j.jhep.2005.11.025_bib79","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1097\/00002030-200011100-00011","article-title":"Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects, ACTG 884","volume":"14","author":"Fletcher","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2005.11.025_bib80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2125.2000.00302.x","article-title":"The intracellular activation of lamivudine (3TC) and determination of 2\u2032-deoxycytidine-5\u2032-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells","volume":"50","author":"Kewn","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2005.11.025_bib81","unstructured":"Flaherty J, Kearney B, Wolf J, et al. Coadministration of tenofovir DF and didanosine: a pharmacokinetic and safety evaluation. 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, USA; December 2001. [Abstract I-1729]."},{"key":"10.1016\/j.jhep.2005.11.025_bib82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1086\/368313","article-title":"Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine","volume":"36","author":"Murphy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib83","unstructured":"Kearney BP, Damle B, Plummer A, Sayre J, Zhang X, Ryan K, et al. Tenofovir DF and didanosine EC: investigation of pharmacokinetic drug-drug and drug-food interactions. 14th international AIDS conference, Barcelona, Spain; July 2002. [Abstract LbPeB9026]."},{"key":"10.1016\/j.jhep.2005.11.025_bib84","unstructured":"Kearney BP, Isaacson E, Sayre J, Namini H, Cheng A. Didanosine and tenofovir DF drug\u2013drug interaction: assessment of didanosine dose reduction. 10th conference on retroviruses and opportunistic infections, Boston, USA; February 2003. [Abstract 533]."},{"key":"10.1016\/j.jhep.2005.11.025_bib85","unstructured":"Kaul S, Damle B, Bassi K, et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules in combination with tenofovir disoproxil fumarate and food for a once-daily antiretroviral regimen. Fourth international workshop on clinical pharmacology of HIV therapy, Cannes, France; March 2003. [Abstract 54]."},{"key":"10.1016\/j.jhep.2005.11.025_bib86","first-page":"233","article-title":"Didanosine plasma levels in patients taking tenofovir concomitantly: high interindividual variability but association with hyperlactatemia","volume":"5","author":"Rendon","year":"2004","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2005.11.025_bib87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/376991","article-title":"Pancreatitis with didanosine and tenofovir disoproxil fumarate","volume":"37","author":"Blanchard","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib88","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1D616","article-title":"Acute onset of pancreatitis with concomitant use of tenofovir and didanosine","volume":"38","author":"Kirian","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jhep.2005.11.025_bib89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0140-6736(04)16608-7","article-title":"Unexpected drug interactions and adverse events with antiretrovial drugs","volume":"364","author":"Moyle","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(04)16591-4","article-title":"Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults","volume":"364","author":"Martinez","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.11.025_bib91","first-page":"S172","article-title":"Early virological failure and occurrence of resistance in na\u00efve patients receiving tenofovir, didanosine and efavirenz","volume":"9","author":"Podzamczer","year":"2004","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2005.11.025_bib92","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.48.4.1089-1095.2004","article-title":"Role of purine nucleoside phosphorylase in interactions between 2\u2032,3\u2032-dideoxyinosine and allopurinol, ganciclovir, or tenofovir","volume":"48","author":"Ray","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2005.11.025_bib93","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1592\/phco.23.6.695.32189","article-title":"Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells","volume":"23","author":"Robbins","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jhep.2005.11.025_bib94","unstructured":"Reyataz Summary of Product Characteristics. Bristol Myers Squibb Pharmaceuticals Ltd; July 2004."},{"key":"10.1016\/j.jhep.2005.11.025_bib95","unstructured":"Reyataz Prescribing Information. Bristol Myers Squibb Co.; July 2004."},{"key":"10.1016\/j.jhep.2005.11.025_bib96","unstructured":"Alexander CS, Montaner JG, Langridge S, Guillemi SA, Harris M, Harrigon H, et al. Interaction between atazanavir\u2013ritonavir and nevirapine is observed in a clinical setting. Seventh international congress on drug therapy in HIV infection, Glasgow, Great Britain; November 2004. [Abstract P275]."},{"key":"10.1016\/j.jhep.2005.11.025_bib97","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2005.11.025_bib98","unstructured":"Taburet AM, Piketty C, G\u00e9rard L, Vincent I, Chazallon C, Clavel F, et al. Pharmacokinetic parameters of atazanavir\u2013ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a sub-study of Puzzle2-ANRS 107 trial. 10th conference on retroviruses and opportunistic infections, Boston, USA; February 2003. [Abstract 537]."},{"key":"10.1016\/j.jhep.2005.11.025_bib99","unstructured":"Kaul S, Bassi K, Damle B, Xie J, Gale J, Kearney BP, et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine and tenofovir disoproxil fumarate for a once daily antiretroviral regimen. 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, USA; September 2003. [Abstract A-1616]."},{"key":"10.1016\/j.jhep.2005.11.025_bib100","unstructured":"Viread Summary of Product Characteristics. Gilead Sciences International Ltd; June 2004."},{"key":"10.1016\/j.jhep.2005.11.025_bib101","unstructured":"Breilh D, Rouzes A, Djabarouti S, Pellegrin I, Xuereb F, Coupet A, et al. Pharmacokinetic drug interaction of lopinavir\u2013ritonavir in combination with tenofovir in experienced HIV-positive patients. 44th interscience conference on antimicrobial agents and chemotherapy, Washington, USA; October\u2013November 2004. [Abstract A-445]."},{"key":"10.1016\/j.jhep.2005.11.025_bib102","unstructured":"Scarsi K, Postelnick M, Murphy R. Comparison of lopinavir\u2013ritonavir plasma levels with and without tenofovir as part of HAART in HIV-1 infected patients. Fifth international workshop on clinical pharmacology of HIV therapy, Rome, Italy; April 2004. [Abstract 26]."},{"key":"10.1016\/j.jhep.2005.11.025_bib103","unstructured":"Kearney BP, Mittan A, Sayre J, Flaherty JF, Zhong L, Toole JJ, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir\u2013ritonavir. 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, USA; September 2003. [Abstract A-1617]."},{"key":"10.1016\/j.jhep.2005.11.025_bib104","unstructured":"Zong J, Chittick G, Blum MR, Hill D, Begley J, Adda N, et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjects. 44th interscience conference on antimicrobial agents and chemotherapy, Washington, USA; October\u2013November 2004. [Abstract A-444]."},{"key":"10.1016\/j.jhep.2005.11.025_bib105","unstructured":"Kearney BP, Isaacson E, Sayre J, Ebrahimi R, Cheng AK. The pharmacokinetics of abacavir, a purine nucleoside analogue, are not affected by tenofovir DF. 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, USA; September 2003. [Abstract A-1615]."},{"key":"10.1016\/j.jhep.2005.11.025_bib106","unstructured":"Kearney BP, Flaherty J, Wolf J, Sayre J, Gill S, Coakley D. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir\u2013ritonavir in healthy subjects. Eighth European conference on clinical aspects and treatment of HIV infection, Athens, Greece; October 2001. [Poster 171]."},{"key":"10.1016\/j.jhep.2005.11.025_bib107","unstructured":"Roszko PJ, Curry K, Brazina B, Cohen A, Turkie EL, Sabo JP, et al. Standard doses of efavirenz, zidovudine, tenofovir, and didanosine may be given with tipranavir\u2013ritonavir. Second IAS conference on HIV pathogenesis and treatment, Paris, France; 2003. [Abstract 865]."},{"key":"10.1016\/j.jhep.2005.11.025_bib108","unstructured":"Smith P, Kearney B, Cloen D, Booker B, Liaw S, Yale K, et al. Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. Second IAS conference on HIV pathogenesis and treatment, Paris, France; 2003. [Abstract 869]."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805007506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805007506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T18:29:47Z","timestamp":1683311387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827805007506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":108,"alternative-id":["S0168827805007506"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2005.11.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}